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Introduction
Our goal is to eliminate the tumor by combining vaccination with local ablation to render long-term immune protection without excessive autoimmune sequelae. Complimenting this regimen is systemic modulation of regulatory T cells (Treg) and intratumoral expression of immune augumenting molecules. We tested two related hypotheses in the specific aims.
Aim 1 Test the hypothesis that cryosurgery of cytokine enriched tumors amplifies Her-2 vaccine response. Aim 2 Test the hypothesis that disabling iTreg conversion enhances Her-2 immunity, not autoimmunity
Body
Aim 1 Test the hypothesis that cryosurgery of cytokine enriched tumors amplifies Her-2 vaccine response. A manuscript describing the findings from this aim has been submitted for publication and is under revision.
To enrich the tumor microenvironment with immune stimulating cytokines, a toll-like receptor 9 (TLR9) agonist CpG oligodeoxynucleotide was injected peritumorally immediately following cryosurgery. A transient elevation of inflammatory cytokines was detected in the plasma of mice receiving CpG ( Figure 7B of the attached manuscript). In BALB/c mice inoculated with TUBO ( Figure 2E ) or D2F2/E2 ( Figure 5F ) mammary tumor, local tumor recurrence following cryosurgery was reduced from 26% and 29% to 0% when CpG was incorporated in the regimen. Similarly, in Her2/neu-tolerant NeuT mice that bear TUBO tumor, addition of CpG to cryoablation reduced tumor recurrence from 71% to 12% ( Figure 3C ). Therefore, local immune stimulation reduced or eliminated residual tumor tissue after cryosurgery. Adaptive immunity is also elevated by CpG as demonstrated by heightened aHer2/neu antibody levels in mice receiving both cryosurgery and CpG ( Figure 3A) .
Below is the manuscript submitted for publication
Cryotherapy with concurrent CpG Oligonucleotide treatment modulates Her2/neu immunity and controls local tumor recurrence
Veenstra JJ, Gibson HM, Littrup PJ, Reyes JD, Cher ML, Takashima A, and Wei WZ
Abstract
Percutaneous cryoablation is a minimally invasive procedure for tumor destruction, which can potentially initiate or amplify antitumor immunity through the release of tumor-associated antigens. However, clinically efficacious immunity is lacking and regional recurrences are a limiting factor relative to surgical excision. We evaluated α-Her2/neu immunity following cryoablation in BALB/c and neu-tolerant NeuT mice inoculated with neu or Her2 expressing mammary tumors TUBO and D2F2/E2 respectively. To promote immune activity local TLR9 activation via peritumoral CpG oligodeoxynucleotide injection was used with cryoablation.
Cryoablation of TUBO primed the host to produce α-neu IgG rendering systemic protection,
INTRODUCTION
As immunotherapy becomes a mainstay in cancer therapy, attention is directed to immune constituents in the tumor microenvironment, particularly the modulation of their activities to enhance treatment outcome. In parallel with this progress is the advancement in image guided percutaneous cryoablation that utilizes ultra-cold temperatures to precisely destroy cancers of the breast, prostate, kidney, liver, bone, lung, brain, and skin (1).
Cryoablation directly induces necrosis by damaging cell membranes and organelles via the formation of ice crystals, and indirectly through osmotic stress and ischemia from thrombosis of the microvasculature (2). Compared to surgical resection, cryoablation is minimally invasive, places less stress on the body, allows for quicker recovery, and is less costly (3) . In addition to debulking the tumor, the necrotic tissue becomes a rich reservoir of tumor-associated antigens that are cleared by antigen presenting cells (APCs), creating a unique opportunity to prime or boost systemic antitumor immune responses, which may afford increased survival (4).
Induction of systemic immunity was initially observed in the 1970's when several patients had metastatic lesions regress following cryoablation of primary prostate tumors (5, 6) . Further support of 'cryoimmunology' was linked to an increase in antibodies against DNA, RNA, and tumor cells in patients receiving palliative cryoablation for advanced cancer (7) . More recently a study following 20 prostate cancer patients observed elevated levels of circulating inflammatory cytokines and cellular immunity after cryotherapy but found the response was transient and unable to prevent disease relapse (8) . In a separate study, cryoablation of metastatic renal cell carcinoma resulted in elevated T-cell and antibody (Ab) responses without affecting the growth of untreated foci (9) . While these results stimulated interest in the immunostimulatory potential of cryoablation, mechanisms leading to beneficial immunity have yet to be elucidated.
Although enhanced immune priming after cryoablation has been described in a number of pre-clinical studies (10) (11) (12) , just as many studies indicate that cryoablation does not elicit any change in tumor-specific immunity (13) (14) (15) , or worse, induces immune suppression and tumor progression (16) (17) (18) . The inconsistencies in tumor-specific immunity and rejection of distant tumors reflect an inadequate understanding of the mechanisms of immune priming and suppression associated with cryoablation. The discrepancy in findings is, at least in part, due to the wide range of tumor models assessed and their varying immunogenicity in respective hosts.
To begin elucidating and exploiting the immunological mechanisms of cryotherapy, we evaluated antitumor immunity following cryoablation of BALB/c mouse mammary adenocarcinomas TUBO and D2F2/E2, which respectively express rat neu and human Her2
and exhibit well-characterized immunogenicity in wild type (WT) and neu tolerant transgenic mice. To further amplify and modulate cryoablation induced immunity, we also tested a Toll-like receptor (TLR) 9 agonist, CpG oligodeoxynucleotides. Dendritic cells (DC) and B-cells are the primary cell types that express TLR9, although mice have additional expression on monocytes and macrophages (19) . Activation of these cells by CpG initiates stimulatory pathways that results in the indirect maturation, differentiation, and expansion of additional DCs, T-cells, NK cells, and macrophages (20) (21) (22) . These cells subsequently secrete cytokines that generate a pro-inflammatory and strongly Th1 biased environment (22, 23 
MATERIALS AND METHODS
Mice: Female BALB/c mice (6-8 week old) were purchased from Charles River Laboratory.
Heterozygous C57BL/6 pIL-1β-DsRed transgenic mice have previously been described (29) .
Heterozygous IL-1β-DsRed (BALB/c x C57BL/6) F1 mice were generated by crossing Percryo CryoProbe -round ice (Endocare). Briefly, an ellipse of skin over the tumor was removed, and the tumor was retracted from the hind limb, peritoneal membrane, and adjacent skin without interrupting tumor vasculature. The cryoprobe was longitudinally inserted through the center of the tumor and freezing was initiated at 100% power. Each freeze cycle was administered for a full minute, reaching -150°C in the probe, followed by the thawing cycle, which lasted until the probe could be freed from the tumor (~1 minute). After two freeze-thaw cycles were completed, the skin was closed over the tumor. Sham surgery was performed without freezing and thawing. Surgical excision was performed using electrocautery to remove the tumor and adjacent mammary tissue. All incisions were closed using surgical staples.
CpG ODN mu2395:
The murine specific class C CpG sequence: Statistical analysis: Statistical analyses were conducted using GraphPad Prism 6. Error bars shown represent SEM unless otherwise noted. Survival percentages were calculated using the Kaplan-Meier method (38) . P values less than 0.05, 0.01, and 0.001 are noted as *, **, and ***, respectively.
RESULTS

Necrosis and inflammatory infiltration following tumor cryoablation.
To evaluate cellular responses to cryoablation, BALB/c mice inoculated with neu + TUBO adenocarcinoma were treated with cryoablation and tumors were removed 1, 3, 9, and 29 days later for H&E histology (Fig. 1) . Complete coagulative necrosis in the ablated tissue was evident by the absence of nuclear staining. Consistent with the classical wound healing process, polymorphonucleocytes (PMNs) in the peripheral and perivascular regions of the tumor were apparent 1 day after cryoablation (Fig. 1A) and dissipated by day 3 (39). Macrophage and fibroblast infiltration was evident by day 9 (Fig. 1A) . Over the next 4 weeks, fibroblasts continued to expand and produce collagen, indicative of tissue remodeling.
To detect functional inflammatory infiltrates in cryoablated tumors, D2F2/E2 mammary tumor was inoculated into pIL-1β-DsRed transgenic (BALB/cxC57Bl/6 F1) mice, which utilize IL- (Fig. 1C) . This finding provides direct evidence of IL-1β activation, consistent with infiltration of functional macrophages in ablated tissues.
Cryoablation of TUBO mammary adenocarcinoma induces α-neu IgG and systemic tumor protection.
To test if cryoablation induces systemic tumor immunity, female BALB/c mice were inoculated with neu + TUBO cells. When tumors reached ~60mm 3 they were treated with cryoablation with or without peritumoral CpG injection, CpG alone, surgical excision, or left untreated (n=6-8) (Fig. 2A) . All tumors treated with cryoablation ± peritumoral CpG or surgical excision completely regressed except two mice in the cryoablation group that developed recurrences on day 41 and 57. CpG treatment alone did not cause regression but reduced tumor growth relative to untreated mice (Fig. 2B ).
Once cryoablated tumors had fully resolved (~8 wks), tumor-free mice received a secondary TUBO inoculation on the contralateral side to simulate outgrowth of a distant tumor.
An additional group of naïve mice also received TUBO inoculation as a control (n=7).
Cryoablation of the primary tumor protected 7/11 (64%) mice from secondary inoculation, whereas addition of CpG to cryoablation protected 15/16 (94%) mice (Fig. 2C-D) . Thus, cryoablation of TUBO induced systemic antitumor immunity that was significantly enhanced by concurrent TLR9 stimulation via CpG. In contrast, surgical excision eliminated the primary tumor without triggering immune priming and only 1/6 mice rejected the secondary inoculation. These results suggest cryoablation, but not surgical excision released tumor associated antigens to prime tumor specific adaptive immunity.
In a fraction of cryoablation treated mice it was noted that primary tumors recurred but not if CpG was concurrently used. To further investigate this finding, results were compiled from 4 independent experiments to include mice treated with either cryoablation alone (n=28) or cryoablation and CpG (n=15). All mice were treated when tumors were ~ 60mm 3 and monitored for tumor recurrence for at least 30-90 days (Fig. 2E) . Cryoablation alone had a recurrence rate of ~26%, occuring between 34-60 days. When CpG was combined with cryoablation the recurrence rate fell to 0%. Surgical excision of similar size tumors, produced no detectable recurrences (n=24) (data not shown). Therefore, equivalent long-term recurrence rates as surgical resection can be achieved with cryoablation if CpG is used concurrently.
To determine the mechanism of tumor rejection by cryoablation α-neu humoral and cellular responses were measured. Inoculation and growth of TUBO in untreated mice did not induce α-neu IgG by day 35 when tumors measured ~350 mm 3 ( Supplementary Fig. S1 A), suggesting a block or lack of antigen presentation by the tumor alone. Mice treated with cryoablation produced increased levels of α-neu IgG beginning 14 days post-operatively (16±7 μg/mL) and plateaued thereafter (Fig. 3A) . Peritumoral injection of CpG without cryoablation also induced α-neu IgG (22±7 μg/mL), although tumors failed to regress. When CpG was used in combination with cryoablation, α-neu IgG levels continually increased to 58±16 μg/mL at day 41, which plateaued thereafter and remained elevated to at least day 70, indicating synergy between cryoablation and CpG injection. Area under the curve (AUC) analysis found significant differences occurring between cryoablation + CpG and cryoablation groups, as well as between cryoablation and excision groups. Mice undergoing surgical excision produced very low levels of α-neu IgG (1.5±0.03 μg/mL) similar to untreated tumor bearing mice (Fig. 3A) . ELISPOT analysis of mice treated with cryoablation or cryoablation + CpG showed negligible α-neu IFNγ producing T-cells (not shown). Therefore, cryoablation induced primarily a humoral response which was enhanced by CpG treatment. Because rejection of neu-dependent tumors such as TUBO is mediated primarily through anti-neu Ab as reported by us and others (32, 35, 40) , induction of α-neu Ab by cryoablation may be the primary mechanism for rejecting the secondary tumor. Additionally, cryoablation + CpG induced both IgG1 and IgG2a, whereas cryoablation alone induced primarily IgG1 (Fig. 3B) . These results indicate cryoablation triggers a Th2 biased response which can be shifted toward a Th1 response with addition of CpG.
However, CpG treatment alone was unable to mediate tumor regression despite elevated Ab levels, which argues for tumor debulking.
Cryoablation and α-neu immunity in neu tolerant BALB/NeuT mice.
Cryoablation of neu + TUBO was further tested in BALB/NeuT mice, which express a transforming rat neu and exhibit immune tolerance to neu (30, 31) . Initial studies found cryoablation, with or without peritumoral CpG injection, insufficient to induce α-neu Ab, consistent with their immune tolerance to neu (not shown). As in breast cancer patients, moderate α-neu immunity can be induced in NeuT mice by DNA vaccination (41, 42) .Therefore, we tested if cryoablation impacts vaccine induced immunity in these mice. To establish α-neu immunity, 10 wk old NeuT males were inoculated with TUBO and subsequently electrovaccinated using a hybrid rat neu / human Her2 DNA construct (pNeuE2) at 2 and 4 days after TUBO inoculation (Fig. 4A) . When tumors were ~60mm 3 in size mice were treated with cryoablation ± CpG or excision (n=8). The majority of tumors treated with cryoablation alone recurred after initial regression, whereas only 1/8 mice treated with cryo and CpG developed a recurrence (Fig. 4B) . Results from 2 independent experiments using NeuT males compared recurrence rates of cryoablation alone (n=14), cryoablation and CpG (n=8), and excision (n=7).
All mice were treated when tumors were ~60mm 3 and monitored for tumor recurrence for at least 40 days (Fig. 4C) . Cryoablation alone had a recurrence rate of ~71%, with recurrences detected between 30-43 days after cryoablation. However, when CpG was combined with cryoablation the recurrence rate fell to 12%. No recurrences were detected with excision.
To simulate undetected systemic disease, mice received a secondary TUBO inoculation on the contralateral side 15 days after cryoablation. Neither cryoablation, with or without CpG, nor excision protected mice from secondary tumor growth ( Fig. 4D-E) . Accordingly, no modulation of vaccine induced α-neu IgG was observed after cryoablation ± CpG relative to tumor excision (Fig. 4F) . Thus cryoablation, even with the addition of CpG did not boost vaccine induced antitumor protection. However the addition of CpG to cryoablation reduced recurrences to a similar level as that of excision, indicating a benefit of CpG despite the lack of adaptive immune modulation.
Cryoablation of D2F2/E2 mammary adenocarcinoma
The impact of cryoablation was further tested in D2F2/E2 mammary adenocarcinoma which, unlike TUBO, induces significant levels of α-Her2 IgG1 and splenocyte IFNγ response without exogenous intervention ( Supplementary Fig. S2 ). However, this endogenous α-Her2 immunity is insufficient to prevent progressive tumor growth. BALB/c mice were inoculated with D2F2/E2 cells and tumors were treated on day 13 when they were ~60 mm 3 with cryoablation ± peritumoral CpG, CpG injection alone, tumor excision, or sham surgery (n=6-7) (Fig. 5A ). All tumors treated with cryoablation ± peritumoral CpG or surgical excision completely regressed by day 41 with the exception of one mouse in the cryoablation alone group that developed a recurrence on day 29. CpG treatment alone did not significantly change tumor growth relative to untreated mice (Fig. 5B ).
Once cryoablated tumors had fully resolved (~7 wks), tumor-free mice received a secondary D2F2/E2 inoculation on the contralateral side to simulate outgrowth of a distant
tumor. An additional group of naïve mice also received D2F2/E2 inoculation as a control (n=8).
Treatment of the primary D2F2/E2 tumor with excision or cryoablation ± peritumoral CpG resulted in similar protection from the secondary inoculation (~70-85%) (Fig. 5C ), suggesting that α-Her2 immunity induced by D2F2/E2 tumor growth renders systemic protection once the primary tumor is ablated, regardless of the treatment modality. At study completion (day 59), mice treated with cryoablation ± CpG or tumor excision produced comparable levels of IFNγ after in vitro Her2 stimulation of secondary TDLN, which was significantly elevated relative to naïve mice, illustrating host reactivity to D2F2/E2 tumor growth (Fig. 5D ). Similar to TUBO, AUC analysis of α-Her2 IgG1 found no significant difference between treatment groups, but IgG2a levels were significantly elevated when cryoablation and CpG were used concurrently, further supporting the notion of a Th1 shifted response. These results indicate that α-Her2 immunity is induced by D2F2/E2 tumor growth and elicits systemic protection as long as the primary tumor is eliminated.
Similar to TUBO, primary D2F2/E2 tumors recurred after cryoablation in a fraction of mice, and these results were compiled from 4 independent experiments to include mice treated with either cryoablation alone (n=24) or cryoablation and CpG (n=25). All mice were treated when tumors were ~60mm 3 and monitored for tumor recurrence for at least 30 days and as long as 60 days (Fig. 6E) . Cryoablation alone had a recurrence rate of ~29%, with recurrences detected between 24-58 days. When combined with CpG the recurrence rate fell to 0%, which suggests that CpG elevates antitumor immunity or modifies the tumor microenvironment to prevent recurrences.
Transient tumor promotion after cryoablation
Although cryoablation of D2F2/E2 protected mice from second inoculation once the ablated tumor had completely resolved, the presence of resolving necrotic tumor along with wound healing and inflammation may affect the growth of a co-existing tumor. Thus, we tested the level of tumor protection and growth during the wound healing phase. D2F2/E2 tumorbearing mice were treated as previously described and a second inoculation was administered on day 13 during the wound healing phase (Fig. 6A ). With cryoablation, 1/9 (12%) mice were protected from the second inoculation (Fig. 6B ), compared to protection of 4/5 (80%) mice when inoculated after tumor resolution (day 41) (Fig. 5C ). Addition of CpG in combination with cryoablation resulted in improved protection with 8/16 (50%) mice rejecting the second inoculation, compared to 5/6 (80%) after tumor resolution. Surgical resection protected 3/7 mice versus 5/7 mice when challenged after tumor resolution. Secondary tumors that grew in cryoablation ± CpG treated mice grew at comparable rates to untreated mice, while tumors in the excision group grew significantly slower relative to cryoablation alone (Fig. 6C) . All groups had significantly delayed secondary tumor growth relative to naïve mice, indicating partial tumor inhibition by endogenous α-Her2 immunity (Fig. 6C) . As expected, all tumor-experienced mice produced elevated α-Her2 splenocyte IFNγ responses relative to naïve mice, however there was no significant difference detected between treatment groups. These results suggest resolving necrotic tumor left by cryoablation may transiently promote tumor growth relative to tumor excision, which can partially be abrogated with the addition of CpG.
Peritumoral CpG treatment activates innate immunity
Peritumoral CpG injection reduces cryoablation recurrences independent from adaptive immunity as observed with NeuT mice (Fig. 4) . To evaluate what changes are occurring with CpG administration cytokine responses were examined in plasma on day 2 and 12 after treatment with magnetic-bead multiplexing (Fig. 7A) . On day 2, plasma from mice treated with CpG, either alone or in combination with cryoablation, showed significant increases in IL-1β, IL-6, IL-12, IFNγ, and TNFα relative to all other groups, indicating acute inflammation (Fig. 7B) . By day 12 most cytokines levels had subsided, with the exception of IL-12 which remained significantly elevated with CpG use.
Local and systemic tumor specific immunity was assessed from TDLNs and splenocytes harvested on day 12 with in vitro Her2 stimulation. IFNγ production from TDLN with CpG use, with or without cryoablation, was significantly elevated, but no significant differences were found between treatment groups in splenocytes, suggesting peritumoral CpG effects are primarily regionalized to the injection site with some residual activation of PBMC and transfer to plasma (Fig. 7C ). In line with this notion, more than a 3x increase in circulating DCs (CD11c + ) was observed 2 days after peritumoral CpG treatment with or without cryoablation (Fig. 7D ). Natural killer (NK) cells (CD49b + ) were also found to significantly increase after treatment with cryoablation and CpG. Similar to plasma cytokine levels, this increase in both DCs and NK cells was transient and dissipated by day 12 (not shown). These findings indicate peritumoral CpG injection strongly activates innate immunity and enhances regional adaptive responses.
DISCUSSION
To better understand the principles of cryotherapy and identify areas for therapeutic intervention, immunity induced by cryoablation was interrogated in two BALB/c mammary adenocarcinoma models expressing neu and Her2, TUBO and D2F2/E2 respectively. TUBO is induced by a constitutively activate rat neu and is sensitive to α-neu Ab, but growth of TUBO without intervention did not induce α-neu immunity. Thus, TUBO may resemble Herceptin sensitive breast cancer or others cancers with viral etiology or gene mutations that result in expression of neo-antigens the immune system can recognize but does not without exogenous manipulation (43) . D2F2/E2 expresses human Her2 by transfection and is resistant to α-Her2
Ab but sensitive to T-cells. Growth of D2F2/E2 induces both humoral and cellular immunity which are not sufficient to elicit tumor regression. Thus, D2F2/E2 may be representative of Her2 + tumors which are immunogenic but refractory to Her2 targeted therapy (44, 45) .
Cryoablation of TUBO in WT mice resulted in immune priming, α-neu IgG production, and systemic protection in ~65% mice. In contrast to previous reports (4) resulting immunity was Importantly, tumor recurrences of both TUBO and D2F2/E2 significantly dropped to 0%
in WT mice and to 12% in NeuT mice when CpG was concurrently used. Interestingly, this effect appears to be independent of adaptive immunity based on the lack of immune modulation seen in NeuT mice, as well as cases of mice without tumor recurrence developing secondary tumors upon rechallenge (Fig. 5C ). Furthermore, increased levels of cytokines, including IFNγ and IL-12, correlated with increased levels of circulating DCs and NK cells 2 days after CpG treatment, suggesting activation of innate immunity. Therefore, CpG may act to eliminate tumor recurrences by elevating local innate immune activation as well as adaptive immunity (24, 43) .
For high-risk tumors and oligometastatic disease, local recurrence is a significant clinical consideration for cryoablation (46, 47) . Thus, the added protection provided with CpG may extend cryoablation to benefit a larger patient population.
Cryoablation of D2F2/E2 protected ~80% of mice if secondary inoculation was Th1 response following cryoablation may also improve outcomes with cryoablation. As new immunotherapeutic options emerge, it becomes increasingly important to understand the mechanisms by which cryoablation affects antitumor immunity so an appropriate combination of therapeutic interventions can be used to achieve better clinical outcomes.
Aim 2 Test the hypothesis that disabling iTreg conversion enhances Her-2 immunity, not autoimmunity TIEG1, also known as Kruppel-like transcription factor 10 (KLF10), is essential in TGF-β induced Treg development and bone morphogenesis. Previously, we showed reduced growth of TRAMP-C2 prostate cancer in TIEG1 k/o mice, suggesting enhanced α-tumor immunity with a reduction of TIEG1 mediated iTreg activity. To test if loss of TIEG1 impacts spontaneous tumorigenesis, C57BL/6 TIEG1 k/o mice were crossed with BALB NeuT mice that are heterozygous for a transforming rat neu and develop mammary tumors or salivary tumors. Contrary to the findings with transplanted TRAMP-C2 tumor, TIEG1+/-,NeuT F1 females develop mammary tumors 2-3 wks earlier than their littermates with intact TIEG1. When TIEG1+/-,NeuT F1 mice were back-crossed with TIEG1 k/o mice to produce TIEG1 k/o, NeuT mice, their mammary tumorigenesis was further accelerated.
This accelerated mammary tumorigenesis, with concurrent reduction of iTreg generation, suggests direct and strong inhibition of spontaneous tumorigenesis by TIEG1. Since TGF-β suppresses early phases of mammary tumor progression, TIEG1 may be a critical downstream factor in this pathway also. Analysis of tyrosine kinase activity by RTK signaling array showed similar activation of MAPK, AKT and S6 ribosomal protein in mammary tumors from TIEG1+/-or TIEG1+/+ NeuT mice, suggesting intact neu signaling whether TGF-β signaling is altered. To test the impact of vaccination on tumor progression, male TIEG+/-NeuT F1 and control TIEG1+/+ NeuT F1 mice were electrovaccinated with pNeuE2 which encodes a fusion protein of rat neu and human Her2, to generate comparable levels of α−neu Ab. But, only 3/7 NeuT males with intact TIEG1 developed mammary tumors after vaccination, while 9/10 TIEG1+/-NeuT males developed 1-2 mammary tumors. These results strongly indicate TIEG1 as a tumor suppressor in mammary tumorigenesis. These findings identify TIEG1 as a key factor in
